Sathya Narayanan Patmanathan

Sathya Narayanan Patmanathan

Auto-generated profile, based on publicly available information

Sathya Narayanan Patmanathan

Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cellular Signalling
Verified
Journal Article
Closed access
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
WWWei Wang
Wei Wang
LYLee Fah Yap
Lee Fah Yap
DHDeron Herr
Deron Herr
IPIan Paterson
Ian Paterson

10 May 2016 in Scientific Reports
Verified
Journal Article
Open access
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
SJSteven P. Johnson
Steven P. Johnson
SLSook Ling Lai
Sook Ling Lai
SBSuthashini Panja Bernam
Suthashini Panja Bernam
VLVictor Lopes
Victor Lopes
IPIan Paterson
Ian Paterson
Oral squamous cell carcinoma (OSCC) is a lethal disease with a 5-year mortality rate of around 50%. Molecular targeted therapies are not in routine use and novel therapeutic targets are required. Our previous microarray data indicated sphingosine 1-phosphate (S1P) metabolism and signalling was deregulated in OSCC. In this study, we have investigated the contribution of S1P signalling to the pathogenesis of OSCC. We show that the expression of the two major enzymes that regulate S1P levels were altered in OSCC: SPHK1 was significantly upregulated in OSCC tissues compared to normal oral mucosa and low levels of SGPL1 mRNA correlated with a worse overall survival. Inin vitrostudies, S1P enhanced the migration/invasion of OSCC cells and attenuated cisplatin-induced death. We also demonstrate that S1P receptor expression is deregulated in primary OSCCs and that S1PR2 is over-expressed in a subset of tumours, which in part mediates S1P-induced migration of OSCC cells. Lastly, we demonstrate that FTY720 induced significantly more apoptosis in OSCC cells compared to non-malignant cells and that FTY720 acted synergistically with cisplatin to induce cell death. Taken together, our data show that S1P signalling promotes tumour aggressiveness in OSCC and identify S1P signalling as a potential therapeutic target.

14 July 2015 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
LYLee Fah Yap
Lee Fah Yap
PMPaul G. Murray
Paul G. Murray
IPIan Paterson
Ian Paterson
Almost all drugs approved for use in humans possess potentially beneficial ‘off‐target’ effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re‐purposing FTY720 (also known as fingolimod, Gilenya™), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1‐phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer‐associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti‐cancer agent both in vitro and in vivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer‐related cellular processes, and discuss its potential use as an anti‐cancer drug.

9 December 2016 in Scientific Reports
Verified
Journal Article
Open access
LYLee Fah Yap
Lee Fah Yap
SLSook Ling Lai
Sook Ling Lai
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
RGRavindran Gokulan
Ravindran Gokulan
CRC. Max Robinson
C. Max Robinson
IPIan Paterson
Ian Paterson
Head and neck squamous cell carcinoma (HNSCC) is generalized term that encompasses a diverse group of cancers that includes tumours of the oral cavity (OSCC), oropharynx (OPSCC) and nasopharynx (NPC). Genetic alterations that are common to all HNSCC types are likely to be important for squamous carcinogenesis. In this study, we have investigated the role of the homeodomain-only homeobox gene, HOPX, in the pathogenesis of HNSCC. We show that HOPX mRNA levels are reduced in OSCC and NPC cell lines and tissues and there is a general reduction of HOPX protein expression in these tumours and OPSCCs. HOPX promoter methylation was observed in a subset of HNSCCs and was associated with a worse overall survival in HPV negative tumours. RNAseq analysis of OSCC cells transfected with HOPX revealed a widespread deregulation of the transcription of genes related to epithelial homeostasis and ectopic over-expression of HOPX in OSCC and NPC cells inhibited cell proliferation, plating efficiency and migration, and enhanced sensitivity to UVA-induced apoptosis. Our results demonstrate that HOPX functions as a tumour suppressor in HNSCC and suggest a central role for HOPX in suppressing epithelial carcinogenesis.

22 August 2012 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
PDF file
KCKek Heng Chua
Kek Heng Chua
IHIda Hilmi
Ida Hilmi
LLLay Hoong Lian
Lay Hoong Lian
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
SHSee Ziau Hoe
See Ziau Hoe
KGKhean Lee Goh
Khean Lee Goh

1 October 2018 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
SPSathya Narayanan Patmanathan
Sathya Narayanan Patmanathan
NGNareshwaran Gnanasegaran
Nareshwaran Gnanasegaran
MLMoon Nian Lim
Moon Nian Lim
RHRoslina Husaini
Roslina Husaini
KFKamal Shaik Fakiruddin
Kamal Shaik Fakiruddin
ZZZubaidah Zakaria
Zubaidah Zakaria
The clustered regularly interspaced short palindromic repeats-associated protein 9 or CRISPR/Cas9 system is one of the hottest topics discussed lately due to its robustness and effectiveness in genome editing. The technology has been widely used in life science research including microbial, plant, animal, and human cell studies. Combined with the pluripotency of stem cells, the technology represents a powerful tool to generate various cell types for disease modeling, drug screening, toxicology, and targeted therapies. Generally, the CRISPR/Cas9 system has been applied in genetic modification of pluripotent or multipotent stem cells, after which the cells are differentiated into specific cell types and used for functional analysis or even clinical transplantation. Recent advancement in CRISPR/Cas9 technology has widened the scope of stem cell research and its therapeutic application. This review provides an overview of the current application and the prospect of CRISPR/Cas9 technology, particularly in stem cell research and therapy.